Pharmacogenetic Prediction of Antipsychotic Induced Weight Gain
抗精神病药物引起的体重增加的药物遗传学预测
基本信息
- 批准号:8641427
- 负责人:
- 金额:$ 21.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-04-01 至 2016-02-29
- 项目状态:已结题
- 来源:
- 关键词:AdolescenceAdolescentAdultAdverse effectsAffectAftercareAgeAntipsychotic AgentsAnxiety DisordersAutistic DisorderAwarenessBehavioralBiological MarkersChildCholesterolClinicalCodeColorectal CancerComplexControlled StudyCoronary ArteriosclerosisDataData CollectionDevelopmentDiet MonitoringDiscriminationEpidemiologic StudiesFamilyFatty acid glycerol estersFundingGeneral PopulationGenerationsGenesGenetic MarkersGenotypeHaloperidolHealthHealthcareHeightHip region structureHospitalizationIndividualInstitutionLeadMelanocortin 4 ReceptorMental disordersMeta-AnalysisMetabolicMetabolic syndromeMolecularMood DisordersMorbidity - disease rateMotorNational Institute of Mental HealthObesityPatientsPatternPharmaceutical PreparationsPharmacogeneticsPharmacologyPhenotypePopulation StudyPsychiatryPublic HealthQuality ControlQuantitative Trait LociRelapseResearchRiskRisk FactorsRisk MarkerRisperidoneSample SizeSamplingSchizophreniaSourceSymptomsTimeTreatment EfficacyTriglyceridesVariantWeightWeight GainWorkaripiprazolebaseclinical practicecohortcritical perioddemographicsdesignexperiencegenetic variantgenome wide association studygenome-wideinterestnovelpatient populationprimary outcomepsychologicpublic health relevancequetiapinerisk variantsecondary outcometreatment durationtreatment strategywaist circumference
项目摘要
DESCRIPTION (provided by applicant): The NIMH strategic objectives emphasize the importance of developing strategies for personalized treatment, yet there are currently no widely utilized biomarkers to guide clinicians in the usage of second generation antipsychotic (SGAs). While most SGAs have adequate (though far from perfect) efficacy for the treatment of positive symptoms in schizophrenia, a major concern for patients, families, and clinicians is the burden of antipsychotic-induced weight gain (AIWG). Moreover, the problem of AIWG is a growing public health concern due to the rapidly accelerating use of SGAs for the treatment of non-psychotic conditions in children, adolescents, and adults. Identification of biomarkers predicting AIWG liability are urgently needed for several reasons: 1) the degree of AIWG can be extreme (>14% of baseline weight) in as many as one-fifth of all patients; 2) AIWG can lead to metabolic syndrome and related morbidity; 3) AIWG can be stigmatizing and cause further psychological suffering in patients; and 4) AIWG often leads to medication nonadherence resulting in increased risk of relapse and re-hospitalization. Additionally, the mechanisms underlying AIWG are poorly understood, and the identification of predictive biomarkers can help illuminate the underlying pharmacology, thereby aiding the development of novel medications with reduced AIWG burden. The proposed study aims to identify pharmacogenetic biomarkers for AIWG by analyzing genomewide association study (GWAS) data obtained on 6 cohorts (total n~1200) of prospectively-characterized, SGA- treated patients who are either antipsychotic-na¿ve or have very limited prior exposure. In order to appropriately control for study-specific variables such as
study duration, treatment type, and demographics, GWAS (with appropriate covariates) will be performed in each cohort separately, with results combined via meta-analysis. The relationship of genotype to within-subject changes in BMI will be the primary outcome of interest; secondary outcomes will include antipsychotic-induced changes in other metabolic parameters, including triglyceride levels, cholesterol levels, hip and waist circumference, and fat mass, induced by SGA treatment. Note that no funds in the proposed study are used for subject recruitment, data collection, or genotyping. The proposed study builds upon our recent identification of a genetic biomarker that replicably predicts a doubling of AIWG in carriers of the risk genotype (~20 lbs of weight gain in 12 weeks, as compared to ~10 lbs), utilizing a GWAS based on a much smaller sample size (n=139).
描述(由申请人提供):NIMH战略目标强调制定个性化治疗策略的重要性,但目前还没有广泛使用的生物标志物来指导临床医生使用第二代抗精神病药(SGAs)。虽然大多数SGAs在治疗精神分裂症阳性症状方面有足够(尽管远非完美)的疗效,但患者、家属和临床医生主要关注的是抗精神病药物引起的体重增加(AIWG)的负担。此外,由于SGAs用于治疗儿童、青少年和成人非精神病性疾病的使用迅速增加,AIWG问题已成为一个日益严重的公共卫生问题。由于以下几个原因,迫切需要确定预测AIWG责任的生物标志物:1)多达五分之一的患者的AIWG程度可能非常严重(约为基线体重的14%);2) AIWG可导致代谢综合征及相关发病;3) AIWG可能会给患者带来污名化,并导致进一步的心理痛苦;AIWG常导致药物不依从,从而增加复发和再次住院的风险。此外,AIWG的机制尚不清楚,而预测性生物标志物的鉴定可以帮助阐明潜在的药理学,从而帮助开发减轻AIWG负担的新型药物。该研究旨在通过分析6个队列(共n~1200人)的全基因组关联研究(GWAS)数据,确定AIWG的药物遗传生物标志物,这些队列均为前瞻性特征的SGA治疗患者,这些患者要么是抗精神病药物缺乏,要么之前接触过非常有限。为了适当地控制研究特定的变量,如
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TODD LENCZ其他文献
TODD LENCZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TODD LENCZ', 18)}}的其他基金
Cognitive Genomics as a Window on Neurodevelopment and Psychopathology
认知基因组学作为神经发育和精神病理学的窗口
- 批准号:
9902802 - 财政年份:2019
- 资助金额:
$ 21.06万 - 项目类别:
Cognitive Genomics as a Window on Neurodevelopment and Psychopathology
认知基因组学作为神经发育和精神病理学的窗口
- 批准号:
10360609 - 财政年份:2018
- 资助金额:
$ 21.06万 - 项目类别:
Pharmacogenetic Prediction of Antipsychotic Induced Weight Gain
抗精神病药物引起的体重增加的药物遗传学预测
- 批准号:
8532495 - 财政年份:2013
- 资助金额:
$ 21.06万 - 项目类别:
Common and Rare Genetic Factors in an Ethnically Homogeneous Schizophrenia Cohort
种族同质精神分裂症队列中常见和罕见的遗传因素
- 批准号:
7855944 - 财政年份:2009
- 资助金额:
$ 21.06万 - 项目类别:
Common and Rare Genetic Factors in an Ethnically Homogeneous Schizophrenia Cohort
种族同质精神分裂症队列中常见和罕见的遗传因素
- 批准号:
7941720 - 财政年份:2009
- 资助金额:
$ 21.06万 - 项目类别:
Identifying Molecular Subtypes of Schizophrenia: A Novel Genomic Approach
识别精神分裂症的分子亚型:一种新的基因组方法
- 批准号:
7803674 - 财政年份:2008
- 资助金额:
$ 21.06万 - 项目类别:
Identifying Molecular Subtypes of Schizophrenia: A Novel Genomic Approach
识别精神分裂症的分子亚型:一种新的基因组方法
- 批准号:
7666181 - 财政年份:2008
- 资助金额:
$ 21.06万 - 项目类别:
相似海外基金
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
- 批准号:
10755168 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
- 批准号:
480840 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别:
Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
- 批准号:
10678157 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
- 批准号:
10744412 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
- 批准号:
23K07305 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
- 批准号:
23H02874 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
- 批准号:
10756652 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
- 批准号:
10730872 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
- 批准号:
10650648 - 财政年份:2023
- 资助金额:
$ 21.06万 - 项目类别: